DDInter1939 DDInter782
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinorelbine {u} (Compound) treats {v} (Disease) hematologic cancer
Vinorelbine {u} (Compound) binds {v} (Gene) TUBB4B
Vinorelbine {u} (Compound) upregulates {v} (Gene) LAMC2
Vinorelbine {u} (Compound) is included by {v} (Pharmacologic Class) Vinca Alkaloids
Vinorelbine {u} (Compound) downregulates {v} (Gene) IARS2
Vinorelbine {u} (Compound) causes {v} (Side Effect) Angina pectoris
Vinorelbine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Vinorelbine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Vinorelbine (Compound) resembles Vincristine (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Vinorelbine (Compound) treats hematologic cancer (Disease)
Vinorelbine (Compound) binds TUBB4B (Gene)
Vinorelbine (Compound) upregulates LAMC2 (Gene)
Vinorelbine (Compound) is included by Vinca Alkaloids (Pharmacologic Class)
Vinorelbine (Compound) downregulates IARS2 (Gene)
Vinorelbine (Compound) causes Angina pectoris (Side Effect)
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Modafinil
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin